Logo image of CIGL

CONCORDE INTERNATION-CLASS A (CIGL) Stock Fundamental Analysis

NASDAQ:CIGL - Nasdaq - VGG2452S1002 - Common Stock - Currency: USD

4.21  -1.45 (-25.62%)

After market: 4.04 -0.17 (-4.04%)

Fundamental Rating

0

Overall CIGL gets a fundamental rating of 0 out of 10. We evaluated CIGL against 0 industry peers in the Unkown industry. CIGL may be in some trouble as it scores bad on both profitability and health. CIGL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CIGL has reported a negative cash flow from operations.
CIGL Yearly Net Income VS EBIT VS OCF VS FCFCIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -814.13%
ROE -3966.49%
ROIC N/A
ROA(3y)-271.31%
ROA(5y)N/A
ROE(3y)-1327%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CIGL Yearly ROA, ROE, ROICCIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

CIGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CIGL Yearly Profit, Operating, Gross MarginsCIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

CIGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CIGL has about the same amount of shares outstanding.
CIGL has a worse debt/assets ratio than last year.
CIGL Yearly Shares OutstandingCIGL Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M
CIGL Yearly Total Debt VS Total AssetsCIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

CIGL has an Altman-Z score of -16.19. This is a bad value and indicates that CIGL is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 1.46 is on the high side and indicates that CIGL has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Altman-Z -16.19
ROIC/WACCN/A
WACC9.92%
CIGL Yearly LT Debt VS Equity VS FCFCIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 1M -1M 2M 3M

2.3 Liquidity

A Current Ratio of 1.17 indicates that CIGL should not have too much problems paying its short term obligations.
A Quick Ratio of 1.17 indicates that CIGL should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 1.17
CIGL Yearly Current Assets VS Current LiabilitesCIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

0

3. Growth

3.1 Past

The Revenue has decreased by -1.55% in the past year.
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-1.55%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.55%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CIGL Yearly Revenue VS EstimatesCIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
CIGL Price Earnings VS Forward Price EarningsCIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CIGL Per share dataCIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CIGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONCORDE INTERNATION-CLASS A

NASDAQ:CIGL (7/11/2025, 8:00:00 PM)

After market: 4.04 -0.17 (-4.04%)

4.21

-1.45 (-25.62%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap94.01M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.96
P/FCF N/A
P/OCF N/A
P/B 44.58
P/tB 44.78
EV/EBITDA N/A
EPS(TTM)N/A
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.47
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -814.13%
ROE -3966.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.46%
FCFM N/A
ROA(3y)-271.31%
ROA(5y)N/A
ROE(3y)-1327%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 376.43%
Cap/Sales 10.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 1.17
Altman-Z -16.19
F-Score2
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.55%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6824.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-526.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-171.34%
OCF growth 3YN/A
OCF growth 5YN/A